Press Releases
Eurand Presents Data on ZENPEP(R) Without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients With CF and Pancreatic Insufficiency
Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. announced additional data from a post-hoc analysis of a Phase III clinical...
Industry Reports
ICON reports revenues of $225 million up 2% on prior year
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, reported its financial results for the third quarter...
Press Releases
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL(R) (armodafinil) Tablets and PROVIGIL(R) (modafinil) Tablets...
Industry Reports
Pfizer Entering into a partnership with Laboratorio Teuto Brasileiro S.A to develop and commercialize generic medicines
Pfizer Inc. announced that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to...
News
Sandoz announces launch of piperacillin and tazobactam for injection, a generic version of Zosyn
Sandoz anounced the launch of piperacillin and tazobactam for injection, a generic equivalent of Zosyn®, in the US. Piperacillin and tazobactam for injection is...
Press Releases
FDA approves Herceptin for HER2-positive metastatic stomach cancer
Roche announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil )...
Clinical Trials
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read